Diligence memo · auto-generated · as of July 2, 2026
Sprout2 Inc.
Sprout2 Inc. looks under-valued against its niche peers and is quiet on financing cadence.
Businessfiled
Sprout2 Inc. operates in Pharmaceuticals, based in Raleigh.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Sprout2 Inc. has raised $66M in disclosed capital across 5 recorded rounds, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $28M on 2020-11-25.
Most recent recorded round closed around 2024-12-10.
Valuation (modeled)modeled
Provath models Sprout2 Inc. at approximately $62M (range $22M–$102M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Under-valued. Modeled value is 0.48× the median modeled value of Series B Pharmaceuticals companies in 2022–2024 (51 peers) — value vs value, same stage and era.
Financing rhythm & timingmixed
Historic cadence: a new round about every 12 months.
Last raise 19 mo ago; this sector typically re-raises about every 13 months.
Slightly overdue versus sector cadence.
The last round stepped up 1.5× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 85% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 47% of those peers.
Closest niche peers: MedAvail Holdings, Inc., Revalesio Corp, Kinaset Therapeutics, Inc., Venatorx Pharmaceuticals, Inc., Cxl Ophthalmics, Inc..
Peoplefiled
13 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.